AUTHORS
Daphne Campbell, DO, Dung Phuong Pham2, Lukas Ronner, MD MSCR3, Taylor M Figgs, MD4, Kiyan Alrobaire, BS5, Ian Yoon6, Grace Zhang7, Rick Qian8, Riya Patel9, Chelsea Saia, MPH10, Katharine Rendle, PhD, MPH11, David Porter, MD12, Keith W. Pratz, MD13, Alexander E. Perl, MD14, Alison Loren, MD, MSCE15, Selina Luger, MD, FRCPC16, Catherine Lai, MD, MPH17
AFFILIATIONS
1 Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Vin University, Hanoi, Viet Nam
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
11 Abramson Cancer Center, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
12 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
13 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
14 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
15 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
16 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
17 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Introduction
The emotional distress of diagnosis and physical effects of cancer treatment are known to disrupt quality of life, yet sexual health remains an underexplored topic, particularly among patients with hematologic malignancies. This study aimed to measure patient-reported sexual function using validated instruments and identify gaps in sexual health communication among patients with hematologic malignancies.
Methods
We conducted a cross-sectional study of adults (≥ 18 years) on active treatment or surveillance for a hematologic malignancy at the University of Pennsylvania in Philadelphia, PA between 2024 and 2026. Patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), T-cell lymphoblastic lymphoma, myelodysplastic syndrome, chronic myeloid leukemia (CML), or a myeloproliferative neoplasm were identified through the electronic medical record and invited to complete the survey either during a routine outpatient visit or remotely by email or mail. Responses were captured in REDCap.
Sexual function was measured using the Female Sexual Function Index (FSFI) in women, with sexual dysfunction (SD) defined as a score ≤ 26.55, and the International Index of Erectile Function-5 (IIEF-5) in men, with erectile dysfunction (ED) defined as a score < 22. Continuous variables were summarized as medians with interquartile ranges (IQR), and groups were compared using the Wilcoxon rank-sum test. Associations with age were evaluated using Spearman’s correlation. Open-ended responses assessing pretreatment communication and unmet sexual health informational needs were independently analyzed by two reviewers using directed content analysis and coded into themes. Interrater discrepancies were resolved by consensus.
Results
Among 576 patients invited, 61 eligible patients completed the survey. Median age was 62 years (IQR, 42-73), 64% of participants were men, and 36% were women. The most common diagnoses were AML (38%), CML (26%), and ALL (18%). At survey completion, 45 (74%) patients were receiving treatment, 21 (34%) had completed intensive chemotherapy, and 12 (20%) had undergone allogeneic hematopoietic stem cell transplantation (HSCT).
Sexual function scores were low irrespective of sex: median FSFI score among 21 evaluable women was 18.7 (IQR, 3.2-25.8) and median IIEF-5 score among 36 evaluable men was 17.5 (IQR, 7.3-22.0), both falling below standard thresholds for dysfunction. SD and ED were common, with 16 (76%) women and 25 (69%) men meeting criteria, respectively. Older age was associated with lower IIEF-5 scores (Spearman ρ = -0.54; p < 0.001). FSFI and IIEF-5 scores at the time of survey completion did not differ by history of prior intensive chemotherapy or HSCT (p > 0.05).
Of 46 patients who responded to the pretreatment communication open-ended question, 72% reported that sexual health had not been discussed with their healthcare team, and 39% believed the topic should have been addressed. Among the 33 who reported no discussion, 30% believed one should have occurred. Of 42 patients who responded to the open-ended question assessing whether there was sexual health information they wished they had known, 69% identified an unmet informational need. Notably, 10 of 12 (83%) patients who initially indicated a pretreatment discussion was unnecessary still identified a topic that should have been addressed.
Conclusion
SD and ED were highly prevalent among participants and most reported inadequate communication from healthcare providers regarding the topic. These findings suggest a role for sexual health communication throughout oncologic care, with opportunities for discussion before, during, and after treatment. Relevant counseling topics may include treatment-related safety concerns and hormonal disturbances, with referral for additional therapeutic support to address emotional well-being when appropriate.
This study is limited by its cross-sectional design, which does not allow for comparison of sexual function before and after diagnosis or treatment, and by the potential for recall and self-selection biases. The ideal timing, setting, and healthcare professional to lead these conversations warrant further investigation, and future research will focus on the development and implementation of interventions based on identified unmet needs. Patient recruitment for this study is ongoing.
DISCLOSURES
Daphne Campbell, DO: No relevant conflicts of interest to declare.